Topical drug delivery devices: A review. (March 2018)

• Record Type: Journal Article
• Authors: Bertens, Christian J.F.; Gijs, Marlies; van den Biggelaar, Frank J.H.M.; Nuijts, Rudy M.M.A.
• Is Part Of: Experimental eye research. Volume 168(2018)
• Page Start: 149
• Page End: 160
• Publication Date: 2018-03
• Subjects: Ophthalmic drug delivery -- Eye drop replacement -- Patient compliance -- Drug delivery routes -- Ocular inserts -- Ophthalmic drug delivery devices; Benzalkonium chloride (BAC) -- Cystoid macular edema (CME) -- Ethylenediaminetetraacetic acid (EDTA) -- Ethylene-vinyl acetate (EVA) -- Food and drug administration (FDA) -- 2-Hydroxyethyl methacrylate (HEMA) -- Intraocular lens (IOL) -- Intraocular pressure (IOP) -- Latanoprost punctal plug delivery system (L-PPDS) -- Lipoic acid (LA) -- LA and its choline ester (LACE) -- Medical device regulation (MDR) -- Minimal inhibitory concentration (MIC) -- New ophthalmic delivery system (NODS) -- Non-steroidal anti-inflammatory drugs (NSAIDs) -- Polyethyleneglycol (PEG) -- Polylactic-co-glycolic acid (PLGA) -- Pre-ocular or post-lens tear film (POTF) -- Poly-ε-lysine (pεK) -- Polyvinyl alcohol (PVA) -- Retinal pigment epithelium (RPE) -- Soluble ophthalmic drug inserts (SODI) -- Topical ophthalmic drug delivery device (TODDD) -- Union of soviet socialist republics (U.S.S.R.) -- United kingdom (U.K.); Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2018.01.010
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: For the treatment and prevention of ocular diseases, most patients are treated with conventional drug delivery formulations such as eye drops or ointments. However, eye drops and ointments suffer from low patient compliance and low effective drug concentration at the target site. Therefore, new medical devices are being explored to improve drug delivery to the eye. Over the years, various delivery devices have been developed including resorbable devices, oval- and ring-shaped devices, rod-shaped devices, punctum plugs, contact lenses and corneal shields. Only a few devices (eg. Mydriasert ®, Ozurdex ®, Surodex ®, Iluvien ®, Lacrisert ® and Retisert ® ) have made it to the market while others are being investigated in clinical trials. Altogether, there is a need for enhanced topical drug delivery. Only by working together (academia, industry and authorities) and by exploring parallel strategies (new drug delivery devices, enhanced drug formulations, better understanding of the pharmacokinetic properties), the therapeutic effect of drug treatments can be improved. Highlights: New ophthalmic drug delivery devices are an unmet need. Remove the burden of eye drops, increase patient compliance. The FDA recognizes the need for new ocular drug delivery devices.